Efficacy and Safety of Roxadustat and High-dose rHuEPO in the Treatment of Peritoneal Dialysis Patients with Renal Anemia
Objective:To investigate the efficacy and safety of Roxadustat and high-dose Recombinant Human Erythropoietin(rHuEPO)in the treatment of peritoneal dialysis patients with renal anemia.Method:A total of 60 peritoneal dialysis patients with renal anemia admitted to Pingxiang People's Hospital from July to December 2022 were selected for this study.They were divided into two groups according to random number table method,with 30 cases in each group.The control group was treated with high-dose rHuEPO,and the study group was treated with high-dose rHuEPO combined with Roxadustat.The therapeutic effect and renal function indexes[blood urea nitrogen(BUN),serum creatinine(Scr),β2-microglobulin(β2-MG)],blood nutrition indexes[hemoglobin(Hb),hematocrit(HCT),red blood cell(RBC)count],parathyroid hormone(PTH),iron metabolism indexes[serum ferritin(SF),transferrin saturation(TSAT)]before and after treatment and adverse reactions were compared between the two groups.Result:After treatment,the total effective rate of the study group was 90.00%,which was significantly higher than 63.33%of the control group,the difference was statistically significant(P<0.05).After treatment,Hb,HCT and RBC in the study group were significantly higher than those in the control group,and PTH was significantly lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,SF and TSAT in the study group were significantly higher than those in the control group(P<0.05).After treatment,BUN,Scr and β2-MG in the study group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Roxadustat combined with high-dose rHuEPO can effectively improve the anemia of peritoneal dialysis patients with renal anemia,correct iron metabolism,and have few adverse reactions.
Peritoneal dialysisRenal anemiaRoxadustatRecombinant Human ErythropoietinSecurity
国家科技期刊平台
NSTL
万方数据
